About Us
KUSTE BIOPHARMA is a new biopharmaceutical Clinical Stage company founded by seasoned life sciences entrepreneurs.
The company holds an exclusive worldwide license for the therapeutic use of compounds in inflammatory diseases, with molecules having achieved extensive phase 2 and phase 3 results in the field of inflammatory diseases of eyes and ears.
KUSTE BIOPHARMA wants to expand the use of these molecules to inflammatory urological diseases whose medical needs are currently unmet, such as interstitial cystitis/painful bladder syndrome (IC/PBS).
Existing clinical data also support other possible developments, for example on inflammatory bowel disease (IBD).
KUSTE BIOPHARMA has closed a relevant financial round to launch Phase 2 clinical studies on IC/PBS and preclinical on other applications.
Press releases
KUSTE BIOPHARMA WELCOMES A NEW MEMBER IN ITS BOARD OF DIRECTORS AND...
Lyon France, 09 November 2020: KUSTE BIOPHARMA, the startup specialised in inflammatory diseases, is proud to expand its reach by welcoming a new... read more
09.11.2020 • By Kuste Biopharma
